A global measure of child health-related quality of life: Reliability and validity of the Child Health and Illness Profile - Child Edition (CHIP-CE) global score

Journal of Medical Economics

Volumn 10, Issue 2, 2007, Pages 91-106

  Riley, Anne W ^a,c   Chan, Kitty S ^a   Prasad, Suyash ^b   Poole, Lynne ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ADHD; Child health and illness profile; Children; Health outcomes measures; Health related quality of life; Parents

Indexed keywords

ARTICLE; CHILD; CHILD HEALTH; HUMAN; INSTRUMENTATION; MENTAL DISEASE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RELIABILITY; RISK ASSESSMENT; SATISFACTION; SCORING SYSTEM;

EID: 34447581142     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200710091106     Document Type: Article

References (26)

1. Matza LS, Rentz AM, Secnik K et al. The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. Journal of Developmental and Behavioral Pediatrics 2004; 25: 166-174.
2. Schmidt LJ, Garratt AM, Fitzpatrick R. Child/parent-assessed population health outcome measures: a structured review. Child: Care, Health and Development 2002; 28: 227-237.
3. Starfield B, Riley AW, Green BF et al. The adolescent Child Health and Illness Profile. A population-based measure of health. Medical Care 1995; 33: 553-566.
4. Riley AW, Forrest CB, Rebok GW et al. The Child Report Form of the CHIP-Child Edition: reliability and validity. Medical Care 2004; 42: 221-231.
5. Riley AW, Forrest CB, Starfield B et al. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Medical Care 2004; 42: 210-220.
6. Prasad S, Sonuga-Barke E, Poole L. Atomoxetine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: effects on broader efficacy. In: 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP); 2004; Berlin, Germany (poster presentation).
7. Prasad S, Poole L. Assessing quality of life in children and adolescents with ADHD: SUNBEAM, an open comparative study of atomoxetine and standard therapy. Patient Reported Outcomes Newsletter 2006; 36: 16-19.
8. Prasad S, Poole L, Harpin V et al. A randomised, controlled, open-label study of the broader efficacy of atomoxetine hydrochloride in comparison to standard current therapy in the treatment of attention deficit/hyperactivity disorder (ADHD) in UK children and adolescents. In: 25th Biennial Congress of the Collegium Internationale NeuroPsychopharmacologicum (CINP); 2006; Chicago, IL, USA.
9. Prasad S, Harpin V, Poole L et al. A multicentre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD) Current Medical Research and Opinion 2007; 23: 379-394.
10. McClure A, Prasad S, Poole L et al. Functional outcomes of children with ADHD in the UK: an assessment of health related quality of life. Poster presented at The Royal College of Paediatrics and Child Health Meeting. Archives of Disease in Childhood 2005; 90(Suppl. II): A48.
11. Ralston SJ, Lorenzo MJM. ADORE - Attention-Deficit/Hyperactivity Disorder Observational Research in Europe. European Child & Adolescent Psychiatry 2004; 13(Suppl. 1): 1/36-1/42.
12. Forrest CB, Riley AW, Vivier PM et al. Predictors of children's healthcare use: the value of child versus parental perspectives on healthcare needs. Medical Care 2004; 42: 232-238.
13. Starfield B. Measurement of outcome: a proposed scheme. Milbank Memorial Fund Quarterly 1974; 52: 39-50.
14. Riley AW, Forrest CB, Starfield B, et al. A taxonomy of adolescent health need: reliability and validity of the adolescent health and illness profiles. Medical Care 1998; 36:1237-1248.
15. Ryff CC, Singer B. The contours of positive human health. Psychological Inquiry 1998; 9:1-28.
16. Cohen J. What I have learned so far. American Psychologist 1990; 45:1304-1312.
17. Streiner DL, Norman GR. Health Measurement Scales: a practical guide to their development and use, Volume 2. New York, NY: Oxford University Press, 1994.
18. Anastasi A. Evolving concepts of test validation. Annual Review of Psychology 1986; 37: 1-15.
19. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research 2002; 11: 193-205.
20. McDowell I, Newell C. Measuring Health: a guide to rating scales and questionnaires (2nd Edition) New York, NY, USA: Oxford University Press, 1996.
21. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 1979; 86: 420-427.
22. Norman GR, Streiner DL. Biostatistics: The Bare Essentials (2nd Edition) Toronto, Canada :BC Decker; 2000.
23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
24. National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamphetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13; Technology Appraisal 98, March 2006.
25. Patrick D, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York, USA: Oxford University Press 1993.
26. EMEA European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. London, July 2005. Doc reference: EMEA/CHMP/EWE/139391/2004.